Combo of Novel BET inhibitor and enzalutamide advances in mCRPC pipeline
Exploration of the novel combination continues after early-phase published data showed promising clinical activity.
Exploration of the novel combination continues after early-phase published data showed promising clinical activity.
Video interviews of experts in the field reviewing research being presented at the 2024 AUA Annual Meeting.
The MPS2 models demonstrated negative predictive values of 95% to 99% for cancers of grade group 2 or higher and of 99% for cancers of…
“And [3 out of 5] of those patients who were initially deemed to go on to nephroureterectomy were able to be converted to endoscopic management,”…
“I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are…
“What we find here was that of the patients who had FGFR3 alterations, 67% of them had tumors that responded,” says Surena F. Matin, MD.
Petros also announced that it has received positive feedback from the FDA after the agency’s informal review of Petros’ technology component for self-selection.
The clearance of the IND application for RAG-01 will initiate the launch of clinical trials in the US.
A decision regarding EU marketing authorization is expected by June 2024.
Kevin M. Wymer, MD, highlights 11 studies in stone disease being presented at the 2024 American Urological Association Annual Meeting.
“ARO-HIF2’s ability to target cancer cells, disrupting a key tumor-driving mechanism, illustrates the potential of siRNA technology in oncology,” says James Brugarolas, MD, PhD.